U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06928779) titled 'Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant' on April 08.
Brief Summary: This study will compare the pharmacokinetics (PK) of dazucorilant (CORT113176) between participants with normal hepatic function and participants with hepatic impairment.
Study Start Date: Oct. 08, 2024
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: Dazucorilant
Dazucorilant 300 mg (4 X 75 mg) soft gelatin capsules for oral administration
Recruitment Status: COMPLETED
Sponsor: Corcept Therapeutics
Published by HT Digital Content Services with permission from Health Daily Digest....